Concurrent radiation therapy and chemotherapy, known as chemoradiation, is a common treatment for locally advanced cancers. Adding concurrent chemotherapy can improve the effectiveness of radiation therapy but can also enhance the appearance of toxic side effects. This means that some cancer patients, especially those with comorbidities or poor health status, are ineligible for concurrent chemoradiation. Researchers at Baylor Scott & White Research Institute (BSWRI) are contributing to critical clinical trials to improve the effectiveness of radiation therapy for cancer patients, including those who are not eligible for concurrent chemoradiation.